Zandelisib

{{Short description|Chemical compound}}

{{cs1 config|name-list-style=vanc|display-authors=6}}

{{Infobox drug

| drug_name =

| image = Zandelisib.svg

| width =

| caption =

| pronounce =

| tradename =

| Drugs.com =

| MedlinePlus =

| licence_CA =

| licence_EU =

| DailyMedID =

| licence_US =

| pregnancy_AU =

| pregnancy_category =

| dependency_liability =

| addiction_liability =

| routes_of_administration =

| class =

| ATC_prefix =

| ATC_suffix =

| legal_status = Investigational

| bioavailability =

| protein_bound =

| metabolism =

| metabolites =

| onset =

| elimination_half-life =

| duration_of_action =

| excretion =

| CAS_number = 1401436-95-0

| CAS_supplemental =

| PubChem = 66571003

| IUPHAR_ligand =

| DrugBank = DB18245

| ChemSpiderID = 57617733

| UNII = 8Z28M5SX0X

| KEGG = D12009

| ChEBI =

| ChEMBL = 4650214

| NIAID_ChemDB =

| PDB_ligand =

| synonyms =

| IUPAC_name = 4-[2-(difluoromethyl)benzimidazol-1-yl]-N-[2-methyl-1-[2-(1-methylpiperidin-4-yl)phenyl]propan-2-yl]-6-morpholin-4-yl-1,3,5-triazin-2-amine

| C=31 | H=38 | F=2 | N=8 | O=1

| SMILES = CC(C)(CC1=CC=CC=C1C2CCN(CC2)C)NC3=NC(=NC(=N3)N4CCOCC4)N5C6=CC=CC=C6N=C5C(F)F

| StdInChI = 1S/C31H38F2N8O/c1-31(2,20-22-8-4-5-9-23(22)21-12-14-39(3)15-13-21)38-28-35-29(40-16-18-42-19-17-40)37-30(36-28)41-25-11-7-6-10-24(25)34-27(41)26(32)33/h4-11,21,26H,12-20H2,1-3H3,(H,35,36,37,38)

| StdInChIKey = WPFUFWIHMYZXSF-UHFFFAOYSA-N

}}

Zandelisib is an investigational new drug that is being evaluated to treat follicular lymphoma.{{cite web | title = Zandelisib - MEI Pharma/Kyowa Kirin | url = https://adisinsight.springer.com/drugs/800038809 | work = AdisInsight | publisher = Springer Nature Switzerland AG }} It is a phosphatidylinositol 3 kinase delta inhibitor.{{cite journal | vauthors = Hus I, Puła B, Robak T | title = PI3K Inhibitors for the Treatment of Chronic Lymphocytic Leukemia: Current Status and Future Perspectives | journal = Cancers | volume = 14 | issue = 6 | date = March 2022 | page = 1571 | pmid = 35326722 | pmc = 8945984 | doi = 10.3390/cancers14061571 | doi-access = free }}